Happening now at #AHA25: José Inia leads a digital poster presentation on a preclinical analysis evaluating a combination approach to targeting atherosclerotic plaque lesions. Review the abstract to learn more about our investigational CETP inhibitor: eppro02.ativ.me//web/index.p...

LDL-C isn’t the whole picture. Other factors like LDL particles, ApoB, Lp(a), non-HDL-C, and low HDL-C can contribute to residual ASCVD risk. Learn about each of these factors: www.expectmoreforldl.com/ldl-c-and-be...

ASCVD risk reduction begins with lowering LDL-C, but residual cardiovascular risk remains and contributes to 400,000 deaths in the US each year. To change that trajectory, we’re challenging ourselves to expect more from lipid-lowering therapies. www.expectmoreforldl.com?utm_source=s...

New this weekend at #AHA25: Don’t miss our CSO Dr. John Kastelein’s oral presentation on an analysis of pooled LDL particle data from our Phase 3 program evaluating our investigational CETP inhibitor. Make sure this session is part of your conference plan: eppro02.ativ.me/appinfo.php?...

We closed the third quarter with continued momentum—advancing our clinical programs, sharing new scientific insights, and preparing for what’s ahead. Read our latest corporate update and Q3 2025 financial results: ir.newamsterdampharma.com/news-release...

Even when taking statins, many ASCVD patients face residual cardiovascular risk.

LDL-C is only part of the story. Research published in Frontiers suggests that LDL particle number (LDL-P) is a more accurate predictor of cardiovascular risk than LDL-C. Read the article: www.frontiersin.org/journals/phy...

We’re excited to see our Alzheimer’s disease biomarker data from a prespecified substudy in our BROADWAY clinical trial has been peer-reviewed and published in the Journal of Prevention of Alzheimer’s Disease. 🔓 Read the open access article: www.newamsterdampharma.com/wp-content/u...

Combination lipid-lowering therapy could prevent 330K deaths globally every year, according to a recent meta-analysis. The findings, drawn from data on over 108,000 patients, make a case to rethink the standard treatment approach. Read more: www.mayoclinicproceedings.org/pb-assets/He...

Despite gradual improvements from 2014 to 2023, too many people with ASCVD are falling short of guideline-recommended lipid levels or not receiving treatment. We’re working to close this gap by advancing therapies with the potential to help more people reach their goals. bit.ly/476bTgz

Despite being on lipid-lowering therapies, many patients still have LDL-C levels above recommended targets. This LDL-C Awareness Day, take a moment for your health—talk to your doctor and see if it's time for a cholesterol check.

This World Heart Day, we’re joining the global call to reduce the burden of cardiovascular disease, the world’s leading cause of death. Our mission: advance research in pursuit of a future where heart disease is no longer the #1 killer. Learn more at bit.ly/3VCUu8V

A new analysis in @jme-journal.bsky.social identifies a costly gap in heart health. A majority of Americans with hypercholesterolemia are on statins, but most don't hit their LDL-C targets. Getting to goal was associated with a 50% reduction in cardiovascular events. bit.ly/48xvWWf

>7M Americans live with Alzheimer’s, and that number could reach 13M by 2050. Cholesterol plays a critical role in brain health, and research suggests there could be a link between lipid metabolism in the brain and Alzheimer’s. Take a closer look at the science: bit.ly/3KhaOty

Nimble, agile, and locked in with our patient focus. Our Chief Commercial Officer BJ Jones shares some of what makes our culture unique, from having a still-practicing clinician as CEO, to the clarity of our shared mission. Learn more about us: www.newamsterdampharma.com/aboutus?utm_...

We’re excited to join the patients, clinicians, and researchers gathering for #FHFSummit25 with the goal of “Catalyzing Collective Action for Lp(a) & FH.” As sponsors, we look forward to being part of conversations that lead to meaningful change. familyheart.org/2025-family-...

Addressing cholesterol dysregulation in the brain may help delay the formation of amyloid plaque and tau tangle buildup that contributes to Alzheimer’s disease. Explore the science: bit.ly/42naX4D

Watch and listen as our leaders participate in fireside chats at three upcoming investor conferences—all before the end of the week. Live webcasts will be available through our website. Mark your calendar: ir.newamsterdampharma.com/news-release...

Prof Stephen Nicholls shared major adverse cardiovascular event (MACE) outcomes based on an analysis of pooled data from our Phase 3 BROOKLYN & BROADWAY studies of our investigational drug therapy, obicetrapib. The data were also simultaneously published in @jaccjournals.bsky.social: bit.ly/4mHrXeb

Tomorrow at #ESCCongress, Professor Kausik Ray will discuss data on our investigational CETP inhibitor as an add-on to background lipid-lowering therapies in a pooled analysis of our BROADWAY and BROOKLYN trials. esc365.escardio.org/esc-congress...

We’re looking forward to #ESCCongress, where our data will be featured in multiple sessions. Presentations will cover: ❤️ MACE data from our BROADWAY and BROOKLYN studies ❤️ CETPi as an add-on LLT in the BROADWAY and BROOKLYN studies More: ir.newamsterdampharma.com/news-release...

ApoE, a protein encoded by the APOE gene, helps transport and clear cholesterol. The APOE4 variant is less efficient in these tasks, increasing the risk for both cardiovascular and Alzheimer’s disease. Learn more about APOE4, cholesterol, and the brain: bit.ly/45pvqrA

Lowering LDL-C is about reducing the risk of cardiovascular events and the need for costly interventions – not just hitting a target. Dr. Maya Safarova says goal attainment should be the standard, not the exception. Explore the unmet need for lipid-lowering therapies: bit.ly/45nfohR

The Marketing Authorization Applications for obicetrapib monotherapy and the obicetrapib-ezetimibe combination have been accepted for review by the European Medicines Agency. We continue to work with Menarini to bring these investigational therapies to patients in Europe. bit.ly/3UuGCNp

Did you know cholesterol plays a critical role in brain health? While it’s essential, too much or poorly regulated cholesterol can contribute to the buildup of amyloid plaque and tau tangles, key markers of Alzheimer’s disease. Explore how cholesterol works in the brain: bit.ly/3UtDJwk

We’re excited to welcome Michael Marino as our new Chief Legal Officer. His experience guiding biotech programs from clinic to commercialization will be key as we move toward launch. Learn more about Mike here: bit.ly/3JtmJDU

A growing body of research indicates CETP plays a central role in both systemic and brain lipid metabolism. Genetic studies show those with naturally low CETP levels are at a lower risk of Alzheimer’s disease, particularly in ApoE4 carriers. Learn more: www.newamsterdampharma.com/lipid-relate...

p-Tau217 is emerging as an important biomarker that can be used to help diagnose and monitor Alzheimer’s disease progression. Levels increase years before memory symptoms appear, making it a helpful indicator for early detection. Get to know this powerful biomarker: bit.ly/47cfrOK

BREAKING: Our investigational CETP inhibitor significantly delayed progression of p-Tau217, an Alzheimer’s disease biomarker, in a 12-month prespecified analysis of data from our BROADWAY ASCVD trial. Effects were most pronounced in ApoE4 carriers. Explore our findings: bit.ly/4mkLIrs

The curtain is about to rise at #AAIC2025, where full results from the Alzheimer’s biomarker prespecified analysis from our BROADWAY LDL-C lowering study will be shared in a Developing Topics oral presentation. Make plans to join us at AAIC: bit.ly/454GysA

Reducing high LDL-C is an essential part of mitigating cardiovascular risk, but as our Chief Scientific Officer Dr. John Kastelein explains, it’s not the only factor. Learn more about residual risk: bit.ly/3IrTeBZ

Lowering LDL-C isn’t just about the numbers—it’s about protecting your health. Even small reductions can make a meaningful difference in lowering your risk of heart attack or stroke. Learn more about the benefits of LDL-C reduction: bit.ly/3TwpZR3

Statins can be a solid start to lipid-lowering therapy, but many patients need more. Doubling the dose only lowers LDL-C by an additional 6%, and that pattern holds even at 4x and 8x the dose. See the effect of therapy with statins on LDL cholesterol levels: pubmed.ncbi.nlm.nih.gov/21977270/#&g...

We wrapped up an energizing R&D Day with a bang, a bell, and confetti as our team gathered around the Nasdaq podium to bring trading to a close. This is the enthusiasm we’re bringing to our work to advance a new era of treatment for cardiovascular disease and other lipid-related conditions.

We’re pleased to share positive topline results from our Alzheimer's Disease biomarker analyses in the Phase 3 BROADWAY trial. Full results will be presented on July 30th at #AAIC2025. Learn more about the study: bit.ly/3HrEanE

We’re proud to celebrate Chris Deluzio, our EVP of Sales and Enterprise Operations, as a 2025 Veeva Hero. From pioneering new tools like Vault CRM and Campaign Manager to helping to shape the future on Veeva’s Advisory Board, Chris leads with heart, vision, and purpose. bit.ly/3SSqlRH

Residual risk—which includes lipid levels like Lp(a)—describes everything that still has the potential to increase cardiovascular risk once LDL-C has been addressed. Learn about these additional risk factors associated with cardiovascular disease. bit.ly/4jqWfzG

We’re excited to see data from our Phase 3 BROADWAY study shared in a late-breaking oral presentation at #NLASessions. Discover what we’ve learned in this study of 2,500 patients at high risk for cardiovascular disease. www.newamsterdampharma.com/wp-content/u...

A pooled analysis from three of our Phase 3 studies evaluated obicetrapib’s effect on Lp(a) in people at increased risk for cardiovascular disease, particularly in those with baseline Lp(a) from 50-150 nmo/L. See the data shared at #NLASessions: www.newamsterdampharma.com/wp-content/u...

New at #NLASessions: An analysis of pooled data from our Phase 3 program related to obicetrapib’s impact on HbA1c and new onset diabetes in patients with prediabetes and normoglycemia at baseline on a background of mostly high-intensity statins. See the poster: bit.ly/4jnLLkb

Data from two of our completed Phase 3 studies—BROOKLYN and BROADWAY—are coming back for an encore at #NLASessions! Learn about the efficacy, safety, and tolerability of our lead investigational asset in populations at high risk for cardiovascular disease. bit.ly/4dDiWz3

We're eager to touch down in Miami for #NLASessions, where insights from two of our completed Phase 3 studies—BROOKLYN and BROADWAY—will be shared along with 9 additional analyses. We hope to see you in The Magic City next week! @nationallipid.bsky.social

Heart disease remains the leading cause of death for women worldwide. This JACC state-of-the-art review explores strategies to address the global burden of heart disease in women, highlighting the need for improved awareness, research, & tailored prevention efforts. #WomensHealthMonth bit.ly/4jfrQUu

1 in 4 U.S. adults—over 63 million people—have high LDL-C, a key driver of cardiovascular disease. Managing cholesterol isn’t just about numbers—it’s about taking action to reduce your risk of a cardiovascular event. Learn why LDL-C control matters and what you can do: bit.ly/NewAmExpectM...

LDL-C is only one piece of the lipid puzzle. In this HCPLive video, a panel of experts breaks down why VLDL, HDL, triglycerides, non-HDL, and ApoB matter, and how they can change the way we approach the prevention and treatment of cardiovascular disease. www.hcplive.com/view/other-l...

Our CFO Ian Somaiya will participate in the 2025 RBCCM Global Healthcare Conference next week. Join him for a virtual fireside chat on Tuesday, May 20 at 10:00 a.m. ET. A live webcast and archived replay will be available. ir.newamsterdampharma.com/news-release...

Our Phase 3 BROADWAY clinical trial enrolled more than 2,500 patients at high risk for cardiovascular events. Principal Investigator Prof. Stephen Nicholls shares why we included MACE as an exploratory endpoint. Learn more about our clinical programs: bit.ly/3RZQXQf

It’s #NationalLipidDay, a timely reminder of the critical role lipid testing plays in heart health. Brush up on what the numbers on your lipid panel mean, and learn more about lipid measurements from @nationallipid.bsky.social: bit.ly/4j5NvPa

This week, results from our Phase 3 clinical program were shared in late-breaking sessions at #EASCongress2025 and simultaneously published in two prestigious medical journals. Learn more about the data: ir.newamsterdampharma.com/news-release...

Late-breaking data from our Phase 3 BROADWAY clinical trial was presented today at #EASCongress2025 and simultaneously published in the New England Journal of Medicine. Read about the results from our largest Phase 3 study to date: www.nejm.org/doi/full/10....